Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
09 juin 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022...
Signati™ Medical, Inc. Debuts Innovative Bipolar Radio Frequency Sealing Platform at American Urological Association (AUA) Annual Meeting
24 mai 2022 09h00 HE
|
Signati Medical Inc.
Providence, RI, May 24, 2022 (GLOBE NEWSWIRE) -- Signati™ Medical, Inc. is pleased to announce the unveiling of their innovative Sealed Vasectomy Procedure at this year’s AUA Annual Meeting in New...
FullWell Focuses on Male Fertility with Vitality and Virility
25 avr. 2022 12h56 HE
|
FullWell
CONCORD, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- The rate of infertility is increasing and is nearly as common in men as it is in women in the United States. About 9% of American men and 10% of...
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
25 avr. 2022 09h20 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
10 mars 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement
07 déc. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus)...
Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
30 nov. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to...
Douglas Stein, MD Joins Signati Medical, Inc.’s Clinical Advisory Board
22 nov. 2021 12h00 HE
|
Signati Medical Inc.
Providence, RI, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Signati Medical, Inc. is pleased to announce that Douglas Stein, MD has joined their Clinical Advisory Board. Having performed over 45,000...
Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
18 nov. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call...
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
17 nov. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...